Shopping Cart 0
Cart Subtotal
AED 0

BioGaia AB (BIOG B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

BioGaia AB (BioGaia) is a biopharmaceutical company, which develops, markets and sells probiotic products. The company sells its probiotic food supplements and oral health products in various dosage forms including drops, lozenges, tablets, chewable tablets, oral rehydration salts (ORS), straws and infant formulas. BioGaia's products are based on various strains of Lactobacillus reuteri, its patented lactic acid bacterium. Its products improve the digestive and oral health of children and adults, and controls digestive problems such as colic, regurgitation, diarrhea and constipation. The company' sells its products through distributors in the Americas, Europe and Asia-Pacific. BioGaia is headquartered in Stockholm, Sweden.

BioGaia AB (BIOG B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioGaia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

BioGaia AB, Medical Devices Deals, 2012 to YTD 2018 10

BioGaia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

BioGaia AB, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

BioGaia Extends Licensing Agreement With Nestle For Lactobacillus Reuteri 13

BioGaia Enters into Agreement with Abbott Laboratories De Chile 14

BioGaia Enters into Agreement with Laboratorios Silanes 15

BioGaia Enters Into Distribution Agreement With Ache Labs 16

BioGaia Enters Into Distribution Agreement With Dong Sung For Baby Drops And Tablets 17

BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 18

BioGaia Enters Into Distribution Agreement With Ferozsons Labs For Probiotic Drops And Tablets 19

Licensing Agreements 20

Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 20

BioGaia Enters Into Licensing Agreement With Nestle 21

BioGaia Enters Into Licensing Agreement With Nestle For Lactobacillus Reuteri 22

BioGaia Enters Into Licensing Agreement With Nestle Mexico For ProTectis 23

Equity Offering 24

Infant Bacterial Therapeutics Raises USD52.4 Million in Rights Offering of Shares 24

Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 26

Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 28

BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 29

BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 30

Acquisition 31

BioGaia Acquires Additional 26% Stake in MetaboGen for USD1.4 Million 31

BioGaia Acquires Additional 9% Stake in MetaboGen for USD0.43 Million 32

BioGaia Acquires Additional 12% Stake in MetaboGen for USD0.5 Million 33

BioGaia Acquires 15% Stake in MetaboGen for USD0.5 Million 34

BioGaia Acquires Remaining 50% Stake In TwoPac 35

BioGaia AB-Key Competitors 36

BioGaia AB-Key Employees 37

BioGaia AB-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 40

Strategy And Business Planning 40

Apr 24, 2018: BioGaia: New initiative in the fight against antibiotic resistance 40

Jun 21, 2017: BioGaia sets up subsidiary for the development of probiotic drugs 41

Financial Announcements 42

Oct 24, 2018: BioGaia-Interim management statement 1 January-30 September 2018 42

Aug 17, 2018: BioGaia-Interim report January 1-June 30, 2018 43

Apr 25, 2018: BioGaia-Interim management statement 1 January-31 March 2018 44

Feb 08, 2018: BioGaia-Year-end report 2017 45

Oct 25, 2017: BioGaia-Interim management statement January 1-September 30, 2017 46

Aug 18, 2017: BioGaia Interim report 1 January-30 June 2017 47

May 03, 2017: BioGaia-Interim management statement 1 January-31 March 2017 48

Feb 10, 2017: BioGaia-Year-end report 2016 49

Corporate Communications 50

May 23, 2018: BioGaia: Management Changes 50

Product News 51

Nov 07, 2017: BioGaia's probiotic shown to promote growth and prevent recurrent diarrhea 51

Oct 08, 2018: MetaboGen reaches development goal-first product ready for safety study 52

Mar 23, 2018: Dr Reddy's launches BioGaia Protectis drops in India 53

Mar 19, 2018: BioGaia's oral health probiotic launched in several European markets as GUM PerioBalance 54

Feb 12, 2018: BioGaia Protectis with vitamin D now available at Apoteket, Apotek Hjartat and Apotea 55

Jan 11, 2018: BioGaia Protectis with vitamin D soon in the Swedish market 56

Other Significant Developments 57

Apr 24, 2018: New Initiative in the Fight Against Antibiotic Resistance 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

BioGaia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioGaia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

BioGaia AB, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

BioGaia AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioGaia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioGaia AB, Deals By Therapy Area, 2012 to YTD 2018 9

BioGaia AB, Medical Devices Deals, 2012 to YTD 2018 10

BioGaia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

BioGaia Extends Licensing Agreement With Nestle For Lactobacillus Reuteri 13

BioGaia Enters into Agreement with Abbott Laboratories De Chile 14

BioGaia Enters into Agreement with Laboratorios Silanes 15

BioGaia Enters Into Distribution Agreement With Ache Labs 16

BioGaia Enters Into Distribution Agreement With Dong Sung For Baby Drops And Tablets 17

BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 18

BioGaia Enters Into Distribution Agreement With Ferozsons Labs For Probiotic Drops And Tablets 19

Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 20

BioGaia Enters Into Licensing Agreement With Nestle 21

BioGaia Enters Into Licensing Agreement With Nestle For Lactobacillus Reuteri 22

BioGaia Enters Into Licensing Agreement With Nestle Mexico For ProTectis 23

Infant Bacterial Therapeutics Raises USD52.4 Million in Rights Offering of Shares 24

Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 26

Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 28

BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 29

BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 30

BioGaia Acquires Additional 26% Stake in MetaboGen for USD1.4 Million 31

BioGaia Acquires Additional 9% Stake in MetaboGen for USD0.43 Million 32

BioGaia Acquires Additional 12% Stake in MetaboGen for USD0.5 Million 33

BioGaia Acquires 15% Stake in MetaboGen for USD0.5 Million 34

BioGaia Acquires Remaining 50% Stake In TwoPac 35

BioGaia AB, Key Competitors 36

BioGaia AB, Key Employees 37

BioGaia AB, Other Locations 38

BioGaia AB, Subsidiaries 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

BioGaia AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

BioGaia AB (BioGaia) is a biopharmaceutical company, which develops, markets and sells probiotic products. The company sells its probiotic food supplements and oral health products in various dosage forms including drops, lozenges, tablets, chewable tablets, oral rehydration salts (ORS), straws and infant formulas. BioGaia's products are based on various strains of Lactobacillus reuteri, its patented lactic acid bacterium. Its products improve the digestive and oral health of children and adults, and controls digestive problems such as colic, regurgitation, diarrhea and constipation. The company' sells its products through distributors in the Americas, Europe and Asia-Pacific. BioGaia is headquartered in Stockholm, Sweden.

BioGaia AB (BIOG B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioGaia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

BioGaia AB, Medical Devices Deals, 2012 to YTD 2018 10

BioGaia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

BioGaia AB, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

BioGaia Extends Licensing Agreement With Nestle For Lactobacillus Reuteri 13

BioGaia Enters into Agreement with Abbott Laboratories De Chile 14

BioGaia Enters into Agreement with Laboratorios Silanes 15

BioGaia Enters Into Distribution Agreement With Ache Labs 16

BioGaia Enters Into Distribution Agreement With Dong Sung For Baby Drops And Tablets 17

BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 18

BioGaia Enters Into Distribution Agreement With Ferozsons Labs For Probiotic Drops And Tablets 19

Licensing Agreements 20

Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 20

BioGaia Enters Into Licensing Agreement With Nestle 21

BioGaia Enters Into Licensing Agreement With Nestle For Lactobacillus Reuteri 22

BioGaia Enters Into Licensing Agreement With Nestle Mexico For ProTectis 23

Equity Offering 24

Infant Bacterial Therapeutics Raises USD52.4 Million in Rights Offering of Shares 24

Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 26

Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 28

BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 29

BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 30

Acquisition 31

BioGaia Acquires Additional 26% Stake in MetaboGen for USD1.4 Million 31

BioGaia Acquires Additional 9% Stake in MetaboGen for USD0.43 Million 32

BioGaia Acquires Additional 12% Stake in MetaboGen for USD0.5 Million 33

BioGaia Acquires 15% Stake in MetaboGen for USD0.5 Million 34

BioGaia Acquires Remaining 50% Stake In TwoPac 35

BioGaia AB-Key Competitors 36

BioGaia AB-Key Employees 37

BioGaia AB-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 40

Strategy And Business Planning 40

Apr 24, 2018: BioGaia: New initiative in the fight against antibiotic resistance 40

Jun 21, 2017: BioGaia sets up subsidiary for the development of probiotic drugs 41

Financial Announcements 42

Oct 24, 2018: BioGaia-Interim management statement 1 January-30 September 2018 42

Aug 17, 2018: BioGaia-Interim report January 1-June 30, 2018 43

Apr 25, 2018: BioGaia-Interim management statement 1 January-31 March 2018 44

Feb 08, 2018: BioGaia-Year-end report 2017 45

Oct 25, 2017: BioGaia-Interim management statement January 1-September 30, 2017 46

Aug 18, 2017: BioGaia Interim report 1 January-30 June 2017 47

May 03, 2017: BioGaia-Interim management statement 1 January-31 March 2017 48

Feb 10, 2017: BioGaia-Year-end report 2016 49

Corporate Communications 50

May 23, 2018: BioGaia: Management Changes 50

Product News 51

Nov 07, 2017: BioGaia's probiotic shown to promote growth and prevent recurrent diarrhea 51

Oct 08, 2018: MetaboGen reaches development goal-first product ready for safety study 52

Mar 23, 2018: Dr Reddy's launches BioGaia Protectis drops in India 53

Mar 19, 2018: BioGaia's oral health probiotic launched in several European markets as GUM PerioBalance 54

Feb 12, 2018: BioGaia Protectis with vitamin D now available at Apoteket, Apotek Hjartat and Apotea 55

Jan 11, 2018: BioGaia Protectis with vitamin D soon in the Swedish market 56

Other Significant Developments 57

Apr 24, 2018: New Initiative in the Fight Against Antibiotic Resistance 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

BioGaia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioGaia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

BioGaia AB, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

BioGaia AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioGaia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioGaia AB, Deals By Therapy Area, 2012 to YTD 2018 9

BioGaia AB, Medical Devices Deals, 2012 to YTD 2018 10

BioGaia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

BioGaia Extends Licensing Agreement With Nestle For Lactobacillus Reuteri 13

BioGaia Enters into Agreement with Abbott Laboratories De Chile 14

BioGaia Enters into Agreement with Laboratorios Silanes 15

BioGaia Enters Into Distribution Agreement With Ache Labs 16

BioGaia Enters Into Distribution Agreement With Dong Sung For Baby Drops And Tablets 17

BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 18

BioGaia Enters Into Distribution Agreement With Ferozsons Labs For Probiotic Drops And Tablets 19

Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 20

BioGaia Enters Into Licensing Agreement With Nestle 21

BioGaia Enters Into Licensing Agreement With Nestle For Lactobacillus Reuteri 22

BioGaia Enters Into Licensing Agreement With Nestle Mexico For ProTectis 23

Infant Bacterial Therapeutics Raises USD52.4 Million in Rights Offering of Shares 24

Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 26

Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 28

BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 29

BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 30

BioGaia Acquires Additional 26% Stake in MetaboGen for USD1.4 Million 31

BioGaia Acquires Additional 9% Stake in MetaboGen for USD0.43 Million 32

BioGaia Acquires Additional 12% Stake in MetaboGen for USD0.5 Million 33

BioGaia Acquires 15% Stake in MetaboGen for USD0.5 Million 34

BioGaia Acquires Remaining 50% Stake In TwoPac 35

BioGaia AB, Key Competitors 36

BioGaia AB, Key Employees 37

BioGaia AB, Other Locations 38

BioGaia AB, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

BioGaia AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.